{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005010","form_type":"8-K","ticker":"BBNX","cik":"0001674632","company_name":"Beta Bionics, Inc.","filed_at":"2026-07-29T20:04:17+00:00","discovered_at":"2026-07-29T20:05:00.776690+00:00","generated_at":"2026-07-29T20:05:10.181589+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Beta Bionics Q2 net sales up 38% to $32M; gross margin expands 524 bps to 59%","bullets":["Net sales $32.0M, up 38% YoY; PBP channel sales surged 153% to $11.6M.","Gross margin 59.0%, up 524 bps from 53.8% in Q2 2025.","Net loss $23.4M (negative 73% of sales) vs $16.9M (negative 73%) YoY.","Adjusted EBITDA negative $17.7M (negative 55% of sales) vs negative $14.5M (negative 63%).","Cash and investments $225.2M as of June 30, 2026; full year 2026 guidance updated (specifics not provided in excerpt)."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005010","json":"https://secwatch.observer/filing/0001171843-26-005010.json","markdown":"https://secwatch.observer/filing/0001171843-26-005010.md","text":"https://secwatch.observer/filing/0001171843-26-005010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674632/000117184326005010/0001171843-26-005010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674632/000117184326005010/f8k_072826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T20:05:10.181589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}